FCGR3A and systemic lupus erythematosus: In searchable articles reports, most of studies on FCGR3A (CD16a) have focused on the pathogenesis, diagnosis, and treatment of inflammatory diseases such as IgG immune complexes (including rheumatoid arthritis and systemic lupus erythematosus), and little attention has been paid to cancer.